Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[NukeJohn]

Possible Short Term Catalysts

Here is a list of possible catalysts on the short term horizon (next month or so):

1. Interim results of ASAP clinical trials. The management of Star Scientific told us in the press release (linked below) that the interim results would be announced mid year. We are now 2 weeks past mid year. I have confidence in this management team and when they state in a company press release that interim results will be released mid year, I believe them. IMHO, these results will be announced within the next month or so.

http://phx.corporate-ir.net/phoenix.zhtml?c=105863&p=irol-newsArticle_print&ID=1659063&highlight=

excerpts...

The nutritional study, which focuses on individuals at risk for inflammatory damage to the thyroid (Hashimoto's thyroiditis), was developed by a team of respected researchers to ensure the scientific quality of the evidence obtained in the study. The ASAP study is expected to be conducted during spring and summer 2012, and an interim look at the data currently is projected for mid-year. This is the second large, multi-site, double-blind, placebo-controlled study involving an Anatabloc(TM) formulation: the Roskamp Institute is conducting the currently enrolling Flint study at sites in Michigan and Florida. The company anticipates a mid-year look at interim data from that study as well.

2. Teaming Agreement with a big pharmaceutical company for a prescription version of Anatabloc. It was announced in a press release 17 months ago they were investigating this option, but these things take time.

excerpts from Feb 2011 Press Release....

S-(-)-anatabine has the potential to be particularly useful for treating disorders involving inflammation that is associated with Nuclear Factor-KappaB (NF-kB) mediated transcription. NF-kB is a transcription factor that operates in cells and participates in the immune response. NF-kB mediated transcription is associated with numerous disorders, including those with inflammatory components, aberrant immune response and/or inappropriate cell proliferation. The provisional application indicates that the disorders which may be treated with this discovery include inflammation occurring in brain swelling or neurodegenerative disease such as Alzheimer's disease, multiple sclerosis and Parkinson's disease.

Recent work at the Roskamp Institute in Sarasota, Florida, has shown that S-(-)anatabine differs in potency from the racemate and is supportive of further development of S-(-)anatabine. Curtis Wright, IV, MD/MPH, Chief Medical Officer of Rock Creek Pharmaceuticals, stated, "We believe that this intriguing development holds within it the seeds of a new drug, and that this preparation of the an active isomer in a commercially viable form is a positive outcome toward that goal."

Star Scientific also is working with McColl Partners LLC on structuring a controlled auction for bidding by pharmaceutical companies for licensing and/or co-venturing relationships.

3. Progress with their Tobacco TSNA Licensing (or an actual settlement with RJ Reynolds or Altria). See this post for my evaluation of the on-going tobacco settlement discussions. Essentially, I think the first Tobacco Company to get a Star TSNAS BDL license has a huge competitive advantage. So, IMHO, the early bird catches the worm.

4. Q2 Earnings Release (coming in less than a month)

5. New Anatabloc skin cream announcement (could be announced at any time). From the Roscea blog entries, we already know it was trial tested by the company and works for Rosacea. Scientists have shown the benefits of stopping transcription of NF-kB for removing wrinkles and thickening the skin. There is anecdotal evidence it works for other conditions like eczema & psoriasis, etc.

6. New Anatabloc line of veterinary products announced. They have already trademarked Anatapup.

7. New celebrity endorsements. For example, Montel Williams "likes" Anatabloc on facebook

8. New Freddie Couples TV commercial (rumored on Yahoo)

9. New reports of parabolic sales growth at GNC (anecdotal reports by numerous posters visiting GNC stores)

10. New peer reviewed articles in Medical Journals (Researchers love to publish their findings)

11. Possible announcement that GNC is launching Anatabloc Worldwide

12. Possible announcement of new retail outlets for Anatabloc (Walgreens, CVS, WalMart, Target, etc.)

13. Major TV coverage of Anatabloc on a show like Dr. Oz or Dr. Drew. We do know that Dr. Lanier is appearing this weekend on Dr. Fisch's show this weekend. FWIW, I think the major health shows on TV alreadu know about Anatabloc and they are waiting for release of clinical trial results.

14. Initiation of coverage of CIGX by a major Wall Street firm. We saw what happened on last week when Carter Worth of Oppenheimer casually added CIGX to his buy list. The stock jumped 40 cents.

15. The stock price could rise above $5 and close there, and the technical traders, major institutions, and hedge funds could jump on board.

I'm sure there are a lot of other potential catalysts I haven't thought about. But, in general, the more things that occur that bring attention to the miraculous ability of Anatabloc to stop the transcription of NF-kB, the more free press Anatabloc and Star Scientific will get. I expect Anatabloc to be the talk of the health media soon after the interim clinical trial results are announced.

These are just a few of the possible catalysts I am looking forward to in the coming weeks. IMHO, now is a good time to add at prices below $5.

Disclosure: Long CIGX

JMHO,

NJ